<p>随着全球市场在谨慎的美联储评论和混合的经济信号中航行，投资者越来越关注在不确定性中识别增长机会。在这样的环境中，拥有高内部持股的公司往往脱颖而出，成为潜在的韧性参与者，因为这可以表明与业务最亲近的人对其长期前景的强烈信心。</p>
<h3>全球高内部持股的十大增长公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.9%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38%</td>
<td>63.7%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们高内部持股快速增长全球公司筛选器中的 847 只股票的完整列表。</p>
<p>在这里，我们突出筛选器中我们首选股票的一个子集。</p>
<h2>苏州泽璟生物制药 (SHSE:688266)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 苏州泽璟生物制药有限公司是一家专注于创新药物的研究、开发和商业化的生物制药公司，市值约为 286.5 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要通过其制药部门产生收入，金额为 6.6791 亿人民币。</p>
<p><strong>内部持股：</strong> 29.4%</p>
<p><strong>收入增长预测：</strong> 每年 38%。</p>
<p>苏州泽璟生物制药展现出显著的增长潜力，预计收入每年增长 38%，超过更广泛的中国市场。尽管在 2025 年上半年净亏损 7280 万元人民币，但收入同比增长至 3.7565 亿元人民币，较去年 2407 万元人民币有所上升。该股票的交易价格大幅低于其估计的公允价值，预计将在三年内实现盈利，尽管近期股价波动仍是投资者需要考虑的因素。</p>
<ul>
<li>在我们的收益增长报告中更详细地了解苏州泽璟生物制药的潜力。</li>
<li>我们的估值报告揭示了苏州泽璟生物制药的股票可能以溢价交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688266 截至 2025 年 9 月的收益和收入增长</p>
<h2>北京瑞普科技 (SZSE:300593)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 北京瑞普科技有限公司在中国和国际上制造和销售电源产品，市值为 100.9 亿人民币。</p>
<p><strong>运营：</strong> 北京瑞普科技有限公司从中国及全球范围内的电源产品制造和销售中产生收入。</p>
<p><strong>内部持股：</strong> 28.8%</p>
<p><strong>收入增长预测：</strong> 每年 32.7%。</p>
<p>北京瑞普科技有望实现显著增长，预计收入每年增长 32.7%，超过更广泛的中国市场增长率。尽管在 2025 年上半年报告净亏损 9514 万元人民币，但公司显示出前景，预测在三年内实现盈利。最近对其章程的修订可能表明战略转变，尽管投资者应注意其高度波动的股价和低预期的股本回报率。</p>
<ul>
<li>通过我们的全面分析师估计报告深入了解北京瑞普科技的复杂性。</li>
<li>我们的全面估值报告提出了北京瑞普科技的定价可能高于其财务状况所能合理化的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown"/></p>
<p>SZSE:300593 截至 2025 年 9 月的持股结构</p>
<h2>POCO 控股 (SZSE:300811)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> POCO 控股有限公司专注于合金软磁粉和电子设备组件的开发、生产和销售，市值为 217.1 亿人民币。</p>
<p><strong>运营：</strong> POCO 控股有限公司主要通过销售合金软磁粉、合金软磁芯和相关电感组件为电子设备产生收入。</p>
<p><strong>内部持股：</strong> 24%</p>
<p><strong>收入增长预测：</strong> 每年 22.7%。</p>
<p>POCO 控股展现出作为增长公司的潜力，预计收入每年增长 22.7%，超过中国市场。尽管其股价波动和预期的股本回报率仅为 18.7%，但预计收益将显著增长，每年增长 26.11%。最近对公司章程的修订表明战略变化，尽管过去三个月没有报告重大内部交易活动。</p>
<ul>
<li>在我们的详细增长预测报告中深入了解 POCO 控股的具体情况。</li>
<li>我们精心准备的估值报告暗示 POCO 控股的股价可能过高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300811 截至 2025 年 9 月的收益和收入增长</p>
<h2>总结</h2>
<ul>
<li>点击这里解锁我们 847 家快速增长全球公司高内部持股的全面列表。</li>
<li>对其他选择感到好奇？特朗普的石油繁荣来了——管道准备好获利。发现 22 只美国股票正在乘风破浪。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论仅基于历史数据和分析师预测，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

铂科新材

泽璟制药-U

<p>随着全球市场面临不确定性，拥有高内部持股的公司因其增长潜力而受到关注。值得注意的公司包括苏州泽璟制药，预计年收入增长 38%，以及北京瑞博科技，预计增长 32.7%。铂科控股预计收入增长 22.7%。尽管近期出现亏损，这些公司在未来盈利方面仍显示出潜力，尽管股价波动仍然是投资者关注的问题</p>

<p>As global markets navigate a complex landscape marked by cautious Federal Reserve commentary and mixed economic signals, investors are increasingly focused on identifying growth opportunities amidst the uncertainty. In such an environment, companies with high insider ownership often stand out as potentially resilient players, as this can indicate strong confidence from those closest to the business in its long-term prospects.</p>
<div class="lb-trans"><p>随着全球市场在谨慎的美联储评论和混合的经济信号中航行，投资者越来越关注在不确定性中识别增长机会。在这样的环境中，拥有高内部持股的公司往往脱颖而出，成为潜在的韧性参与者，因为这可以表明与业务最亲近的人对其长期前景的强烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球高内部持股的十大增长公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.9%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38%</td>
<td>63.7%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.9%</td>
<td>44.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38%</td>
<td>63.7%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>97.5%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 847 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们高内部持股快速增长全球公司筛选器中的 847 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出筛选器中我们首选股票的一个子集。</p>
</div><h2>Suzhou Zelgen Biopharmaceuticals (SHSE:688266)</h2>
<div class="lb-trans"><h2>苏州泽璟生物制药 (SHSE:688266)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a biopharmaceutical company focused on the research, development, and commercialization of innovative drugs, with a market cap of approximately CN¥28.65 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 苏州泽璟生物制药有限公司是一家专注于创新药物的研究、开发和商业化的生物制药公司，市值约为 286.5 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its pharmaceuticals segment, amounting to CN¥667.91 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其制药部门产生收入，金额为 6.6791 亿人民币。</p>
</div><p><strong>Insider Ownership:</strong> 29.4%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 29.4%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 38% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 每年 38%。</p>
</div><p>Suzhou Zelgen Biopharmaceuticals exhibits significant growth potential, with revenue forecasted to increase by 38% annually, outpacing the broader Chinese market. Despite a net loss of CNY 72.8 million in H1 2025, revenue rose to CNY 375.65 million from CNY 240.7 million year-on-year. The stock trades at a substantial discount to its estimated fair value and is expected to achieve profitability within three years, though recent share price volatility remains a consideration for investors.</p>
<div class="lb-trans"><p>苏州泽璟生物制药展现出显著的增长潜力，预计收入每年增长 38%，超过更广泛的中国市场。尽管在 2025 年上半年净亏损 7280 万元人民币，但收入同比增长至 3.7565 亿元人民币，较去年 2407 万元人民币有所上升。该股票的交易价格大幅低于其估计的公允价值，预计将在三年内实现盈利，尽管近期股价波动仍是投资者需要考虑的因素。</p>
</div><ul>
<li>Take a closer look at Suzhou Zelgen Biopharmaceuticals' potential here in our earnings growth report.</li>
<li>Our valuation report unveils the possibility Suzhou Zelgen Biopharmaceuticals' shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的收益增长报告中更详细地了解苏州泽璟生物制药的潜力。</li>
<li>我们的估值报告揭示了苏州泽璟生物制药的股票可能以溢价交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/887c3d2e-7c9f-4df4-849f-db1f7633a463/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688266 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>SHSE:688266 截至 2025 年 9 月的收益和收入增长</p>
</div><h2>Beijing Relpow Technology (SZSE:300593)</h2>
<div class="lb-trans"><h2>北京瑞普科技 (SZSE:300593)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Beijing Relpow Technology Co., Ltd manufactures and sells power supply products both in China and internationally, with a market cap of CN¥10.09 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北京瑞普科技有限公司在中国和国际上制造和销售电源产品，市值为 100.9 亿人民币。</p>
</div><p><strong>Operations:</strong> Beijing Relpow Technology Co., Ltd generates revenue from the manufacturing and sale of power supply products within China and on a global scale.</p>
<div class="lb-trans"><p><strong>运营：</strong> 北京瑞普科技有限公司从中国及全球范围内的电源产品制造和销售中产生收入。</p>
</div><p><strong>Insider Ownership:</strong> 28.8%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 28.8%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 32.7% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 每年 32.7%。</p>
</div><p>Beijing Relpow Technology is poised for substantial growth, with revenue expected to rise by 32.7% annually, surpassing the broader Chinese market's growth rate. Despite reporting a net loss of CNY 95.14 million in H1 2025, the company shows promise with forecasts indicating profitability within three years. Recent amendments to its articles of association may signal strategic shifts, though investors should be mindful of its highly volatile share price and low projected return on equity.</p>
<div class="lb-trans"><p>北京瑞普科技有望实现显著增长，预计收入每年增长 32.7%，超过更广泛的中国市场增长率。尽管在 2025 年上半年报告净亏损 9514 万元人民币，但公司显示出前景，预测在三年内实现盈利。最近对其章程的修订可能表明战略转变，尽管投资者应注意其高度波动的股价和低预期的股本回报率。</p>
</div><ul>
<li>Navigate through the intricacies of Beijing Relpow Technology with our comprehensive analyst estimates report here.</li>
<li>Our comprehensive valuation report raises the possibility that Beijing Relpow Technology is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的全面分析师估计报告深入了解北京瑞普科技的复杂性。</li>
<li>我们的全面估值报告提出了北京瑞普科技的定价可能高于其财务状况所能合理化的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/1bc2d062-4035-4f19-815c-8d4dfef3e358/chart/ownership-breakdown"/></p>
<p>SZSE:300593 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:300593 截至 2025 年 9 月的持股结构</p>
</div><h2>POCO Holding (SZSE:300811)</h2>
<div class="lb-trans"><h2>POCO 控股 (SZSE:300811)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> POCO Holding Co., Ltd. specializes in the development, production, and sale of alloy soft magnetic powder and components for electronic equipment, with a market cap of CN¥21.71 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> POCO 控股有限公司专注于合金软磁粉和电子设备组件的开发、生产和销售，市值为 217.1 亿人民币。</p>
</div><p><strong>Operations:</strong> POCO Holding Co., Ltd. generates revenue primarily from the sale of alloy soft magnetic powder, alloy soft magnetic core, and related inductance components for electronic equipment.</p>
<div class="lb-trans"><p><strong>运营：</strong> POCO 控股有限公司主要通过销售合金软磁粉、合金软磁芯和相关电感组件为电子设备产生收入。</p>
</div><p><strong>Insider Ownership:</strong> 24%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 24%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 22.7% p.a.</p>
<div class="lb-trans"><p><strong>收入增长预测：</strong> 每年 22.7%。</p>
</div><p>POCO Holding demonstrates potential as a growth company, with revenue forecasted to grow at 22.7% annually, outpacing the Chinese market. Despite its volatile share price and low expected return on equity of 18.7%, earnings are projected to increase significantly at 26.11% per year. Recent amendments to the company's articles of association suggest strategic changes, though there is no substantial insider trading activity reported over the past three months.</p>
<div class="lb-trans"><p>POCO 控股展现出作为增长公司的潜力，预计收入每年增长 22.7%，超过中国市场。尽管其股价波动和预期的股本回报率仅为 18.7%，但预计收益将显著增长，每年增长 26.11%。最近对公司章程的修订表明战略变化，尽管过去三个月没有报告重大内部交易活动。</p>
</div><ul>
<li>Dive into the specifics of POCO Holding here with our thorough growth forecast report.</li>
<li>Our expertly prepared valuation report POCO Holding implies its share price may be too high.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的详细增长预测报告中深入了解 POCO 控股的具体情况。</li>
<li>我们精心准备的估值报告暗示 POCO 控股的股价可能过高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/4831af70-abcd-4fa9-8fe8-43d190e41a33/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300811 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:300811 截至 2025 年 9 月的收益和收入增长</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>总结</h2>
</div><ul>
<li>Unlock our comprehensive list of 847 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Curious About Other Options? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里解锁我们 847 家快速增长全球公司高内部持股的全面列表。</li>
<li>对其他选择感到好奇？特朗普的石油繁荣来了——管道准备好获利。发现 22 只美国股票正在乘风破浪。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论仅基于历史数据和分析师预测，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

三家全球增长型公司，内部人士持股比例高，预计收入增长 38%